Cytek Biosciences posted third-quarter 2025 revenue of $52.3 million, up 2% year over year, and expanded its installed base to 3,456 instruments with 161 net adds in the quarter. Revenue from biotechnology, pharmaceutical, and CRO customers grew 14%, while total recurring revenue from service and reagents rose 19%. Growth was broad-based outside EMEA, where demand remained soft. Profitability compressed: GAAP gross margin declined to 53% from 56% and adjusted gross margin to 55% from 60%, with operating expenses up 10% driven by higher G&A. The company reported a net loss of $5.5 million versus a prior-year profit and adjusted EBITDA of $2.5 million, and reaffirmed full-year guidance of $196–$205 million in revenue (down 2% to up 2% versus 2024). Cytek also expanded its European headquarters in Amsterdam by over 40%, adding a customer service and training center.
For pharma leaders, the signal is mixed but meaningful. The topline and installed-base momentum—especially within biopharma and CROs—indicates sustained spend on high-parameter flow cytometry to support immunology, cell and gene therapy, and translational biomarker programs despite tightening capital budgets. At the same time, margin pressure and higher G&A highlight how tools providers are absorbing operating friction while leaning harder on recurring revenue. The strategic question is whether the growing service-and-reagent annuity can offset instrument pricing pressure and macro variability, particularly in EMEA, without starving innovation as R&D and sales and marketing spending pull back.
Why it matters now: sponsors are standardizing advanced cytometry across trial networks to harmonize biomarker readouts, stratify patients, and de-risk pivotal designs. A larger installed base paired with double-digit recurring revenue growth suggests laboratories are locking into defined workflows, a prerequisite for consistent multicenter data and real-world evidence generation. Medical Affairs teams should see the Amsterdam training center as deployment infrastructure—useful for assay standardization, proficiency programs, and education under Europe’s IVDR regime, where validated panels and documentation are increasingly decisive for site activation and payer scrutiny. For CROs, the growth trend underscores outsourcing tailwinds; vendors capable of delivering consistent performance across geographies and sites will win platform standardization mandates that cascade into reagent pull-through.
This update also aligns with broader industry currents: life science tools companies are pivoting to durable annuities and services as biopharma rationalizes capex and concentrates on assets with clearer line-of-sight to value. Competitive intensity remains high, with incumbents pushing clinical-grade claims, integrated software, and automation. Cytek’s strength in spectral cytometry positions it well for high-multiplex immunophenotyping, small-particle detection, and increasingly complex trial endpoints, but most of its portfolio remains research-use-only outside select geographies. With $262 million in cash and marketable securities, the company has room to invest in training, software compliance, and regulatory upgrades—or pursue targeted M&A to accelerate clinical validations and deepen reagent ecosystems.
What to watch next is the strategic bridge from research traction to regulated clinical use. Sponsors and payers are converging on biomarker-driven decisions, and trial decentralization is raising the bar for data integrity, 21 CFR Part 11 readiness, and IVDR alignment. If recurring revenue continues to grow at a high-teens pace while margins stabilize and EMEA demand rebounds, Cytek’s platform could become the default at many trial and translational hubs. If margin compression persists and EMEA softness lingers, expect heavier price competition, deeper partnerships with CROs for bundled solutions, or consolidation moves as vendors race to clinical-grade standardization.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
